These developments are also being spurred by increasingly significant partnerships, like the recently announced Danaher Corporation-Innovative Genomics Institute Beacon for CRISPR Cures, which seeks to build and take to clinic gene editing medicines to treat rare and other diseases.”
Indurthi also predicts the industry will see developments in gene-editing technologies, largely supported by growing partnerships: “Despite the many difficulties associated with gene editing technology, the industry has seen impressive developments in research and the recent approval of the first-ever gene editing medicine is something we are poised to build on. These developments are also being spurred by increasingly significant partnerships, like the recently announced Danaher Corporation-Innovative Genomics Institute Beacon for CRISPR Cures, which seeks to build and take to clinic gene editing medicines to treat rare and other diseases.”